IN­DIA TO BOUNCE BACK AS CLIN­I­CAL RE­SEARCH HUB

BioSpectrum (India) - - BIO CONTENT -

In­dia was con­sid­ered as an all-time favoured des­ti­na­tion for clin­i­cal tri­als. Most of the out­sourced stud­ies are phase III stud­ies where In­dia has a di­verse pool of pa­tients. Af­ter 2010 there was ma­jor set­back in the CRO in­dus­try in In­dia. Drug Con­troller Gen­eral of In­dia (DCGI) ap­provals were de­layed and multi­na­tional spon­sors stepped back out­sourc­ing stud­ies to In­dia. But slowly post 2016 DCGI has been gen­er­ous enough in prov­ing ap­provals and on­line ap­pli­ca­tion sys­tem has brought a lot of dif­fer­ence. In­dian Clin­i­cal Trial mar­ket and clin­i­cal trial ser­vices is ex­pected to grow sig­nif­i­cantly along with trends.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.